Trial 4B-22-5


Phase I Study of Erdafitinib Intravesical Delivery (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Chemotherapy: Local
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Siamak Daneshmand, M.D.
Other Trial Staff:  Cheryl Kefauver, R.N., Monica Flores, D.M., Lusine Raddatz, D.M., Rubina Hassan, D.M., Vicky Araujo, D.M., Lagrimas Ilagan, D.M., Roberto Tejada, D.M., Shamim Jhimlee, Coordinator, Honorina Enright, D.M., Amanda Luna, Coordinator, Ileana Aldana, Coordinator, Hilma Bolton, Coordinator, Bartolo Santos, Coordinator, Viviana Moreno, D.M., Ikechukwu Okereke, Coordinator, Sarah Chevalier, Coordinator, Samantha Escano, Coordinator, Nohely Aldana, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.